MedTrace Logo

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

NCT04922307 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-11-12

No results posted yet for this study

Summary

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT).

The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Conditions

Interventions

PROCEDURE

Blood Sparing Protocol

Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass

PROCEDURE

Standard Blood Replacement

Allogenic blood transfusion as determined intra-operatively

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Kelvin Moses · Associate Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-23
Primary Completion
2025-02-12
Completion
2027-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922307 on ClinicalTrials.gov